OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free CYDY Stock Alerts $0.15 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.14▼$0.1550-Day Range$0.14▼$0.2552-Week Range$0.13▼$0.42Volume410,870 shsAverage Volume1.08 million shsMarket Capitalization$144.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get CytoDyn alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About CytoDyn Stock (OTCMKTS:CYDY)CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Read More CYDY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYDY Stock News HeadlinesMay 4, 2024 | americanbankingnews.comCytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below 50 Day Moving Average of $0.17February 29, 2024 | markets.businessinsider.comCytoDyn Says FDA Lifts Hold On LeronlimabMay 11, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...February 29, 2024 | msn.comFDA lifts clinical hold on CytoDyn drug, stock rallies 22%February 29, 2024 | globenewswire.comCytoDyn Announces FDA Has Lifted Clinical HoldFebruary 10, 2024 | morningstar.comCytoDyn Inc CYDYFebruary 1, 2024 | markets.businessinsider.comCytoDyn Submits Revised HIV Clinical Trial Protocol To FDA, Starts Glioblastoma Pre-Clinical StudyFebruary 1, 2024 | finance.yahoo.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaMay 11, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...February 1, 2024 | tmcnet.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaJanuary 31, 2024 | bizjournals.comInvestors file another lawsuit against CytoDynJanuary 30, 2024 | msn.comCytoDyn Releases Regulatory FD Disclosure InformationJanuary 30, 2024 | msn.comCytoDyn Announces Executive Leadership Changes and AppointmentsJanuary 29, 2024 | bizjournals.comVancouver biotech appoints new CEO, as former top executive awaits fraud trialJanuary 29, 2024 | finanznachrichten.deCytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFOJanuary 29, 2024 | msn.comCytoDyn appoints Jacob Lalezari as CEO, Mitchell Cohen as interim CFOJanuary 29, 2024 | finance.yahoo.comCytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFODecember 7, 2023 | finance.yahoo.comCytoDyn Announces Webcast to Provide Company UpdateNovember 22, 2023 | msn.comCytoDyn appoints Lalezari as its interim CEONovember 21, 2023 | finanznachrichten.deCytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as Interim CEONovember 21, 2023 | finance.yahoo.comCytoDyn Appoints Jacob Lalezari M.D. as Interim CEOSeptember 21, 2023 | bizjournals.comFormer biotech execs in 'brazen fraud' case want indictments dismissedAugust 2, 2023 | fool.comCytoDyn (OTC: CYDY)July 24, 2023 | bizjournals.comCytoDyn leader on taking HIV treatment back to FDA, is upbeat about Amarex litigationJuly 13, 2023 | benzinga.comDevelopments in OTC Stocks Under a Quarter (CSTF, CYDY, IMHC, BRLL)July 12, 2023 | bizjournals.comCytoDyn hits up former business partner for $100M in damagesJuly 11, 2023 | finance.yahoo.comCytoDyn Announces Company Updates and Investment Community Update WebcastSee More Headlines Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today5/11/2024Fiscal Year End5/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIP23283M101 CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-478.47% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$270,000.00 Price / Sales535.41 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-1.21Miscellaneous Outstanding Shares992,870,000Free Float985,823,000Market Cap$144.56 million OptionableNot Optionable Beta0.25 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Cyrus Arman M.B.A. (Age 42)Ph.D., Senior Vice President of Business Operations Comp: $451.17kDr. Jacob P. Lalezari M.D. (Age 64)CEO & Member of Scientific Advisory Board Mr. Mitchell Cohen (Age 67)Interim Chief Financial Officer Mr. Tyler Blok (Age 36)Executive Vice President of Legal Affairs & Secretary Dr. Scott Hansen Ph.D.Head of Research & Basic ScienceMr. Joseph MeidlingExecutive Director of Clinical OperationsMs. Cristina De LeonInvestorsMore ExecutivesKey CompetitorsInterCureNASDAQ:INCRRegulus TherapeuticsNASDAQ:RGLSI-MabNASDAQ:IMABElite PharmaceuticalsOTCMKTS:ELTPCybinNYSEAMERICAN:CYBNView All Competitors CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed in 2024? CytoDyn's stock was trading at $0.1950 at the beginning of 2024. Since then, CYDY shares have decreased by 25.3% and is now trading at $0.1456. View the best growth stocks for 2024 here. Are investors shorting CytoDyn? CytoDyn saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 4,680,600 shares, a decrease of 8.4% from the March 15th total of 5,107,100 shares. Based on an average daily volume of 2,871,500 shares, the days-to-cover ratio is currently 1.6 days. View CytoDyn's Short Interest. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) issued its quarterly earnings results on Monday, April, 15th. The biotechnology company reported ($0.01) earnings per share for the quarter. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA). How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYDY) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.